Approval · Notice of Compliance 1726 · 2003
COZAAR: Notice of Compliance 1726
Issued March 14, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1726
- Date
- March 14, 2003
- Company
- Merck Frosst Canada & Cie, Merck Frosst Canada & Co.Kirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: renal protection in type 2 diabetes with proteinuria
- Therapeutic class
- Angiotensin II receptor antagonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| COZAAR | Not yet assigned | — |
Medicinal ingredients
- LOSARTAN POTASSIUM 25 MG per TAB
- LOSARTAN POTASSIUM 50 MG per TAB
- LOSARTAN POTASSIUM 100 MG per TAB